159 related articles for article (PubMed ID: 18474499)
1. Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir.
Pierone G; Urban T; Martin A; Mieras J; Kantor C
HIV Clin Trials; 2008; 9(2):140-1. PubMed ID: 18474499
[No Abstract] [Full Text] [Related]
2. Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.
Berhan A; Berhan Y
PLoS One; 2013; 8(4):e60814. PubMed ID: 23593314
[TBL] [Abstract][Full Text] [Related]
3. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Arribas JR
Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
[TBL] [Abstract][Full Text] [Related]
4. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.
Walmsley SL; Cotte L; Rusconi S; Ward DJ; Hicks CB; Meier U; Valdez H; Boucher CA
AIDS; 2007 Oct; 21(16):2245-8. PubMed ID: 18090054
[TBL] [Abstract][Full Text] [Related]
5. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
Hill A; Moyle G
HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
[TBL] [Abstract][Full Text] [Related]
6. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
[TBL] [Abstract][Full Text] [Related]
7. Reversal of major genotypic tipranavir mutations under long-term treatment with tipranavir/ritonavir itself with very limited optimized background, during deep salvage antiretroviral therapy.
Sabbatani S; Manfredi R; Fulgaro C; Bon I
Curr HIV Res; 2009 May; 7(3):311-3. PubMed ID: 19442127
[TBL] [Abstract][Full Text] [Related]
8. Relative antiviral efficacy should not be inferred from cross-trial comparisons.
Hall D
HIV Med; 2007 Nov; 8(8):570-1; author reply 571-2. PubMed ID: 17944692
[No Abstract] [Full Text] [Related]
9. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Lascar M; Cartledge JD
J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273
[No Abstract] [Full Text] [Related]
10. Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-264. Methodological accuracy in cross-trial comparisons of antiretroviral regimens in multitreated patients.
Llibre JM; Pérez-Alvarez N
HIV Med; 2007 Nov; 8(8):568-70; author reply 571-2. PubMed ID: 17944691
[No Abstract] [Full Text] [Related]
11. Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).
Delaugerre C; Buyck JF; Peytavin G; Viard JP; Chaix ML; Zucman D; Mortier E; Blanche S; Rouveix E; Force G; Aegerter P; de Truchis P
J Clin Virol; 2010 Mar; 47(3):248-52. PubMed ID: 20097121
[TBL] [Abstract][Full Text] [Related]
12. [Desensitization to tipranavir caused by toxicodermia].
Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
[No Abstract] [Full Text] [Related]
13. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
[No Abstract] [Full Text] [Related]
14. When and how to use tipranavir and darunavir.
Hoffman CJ; Gallant JE
AIDS Read; 2007 Apr; 17(4):194-8, 201. PubMed ID: 17479503
[No Abstract] [Full Text] [Related]
15. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
Temesgen Z; Feinberg J
Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.
Poveda E; Anta L; Blanco JL; Casado JL; Gutiérrez F; García F; Gómez-Sirvent JL; Iribarren JA; Soriano V; de Mendoza C;
Antimicrob Agents Chemother; 2010 Jul; 54(7):3018-20. PubMed ID: 20479204
[TBL] [Abstract][Full Text] [Related]
17. A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide.
Feiterna-Sperling C; Walter H; Wahn V; Kleinkauf N
Eur J Med Res; 2009 Jan; 14(1):44-6. PubMed ID: 19258211
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: The UTILIZE Study.
Baxter JD; Bhatti L; Coakley E; Bartczak J; McDonough M; Vinisko R; Piliero PJ
Curr HIV Res; 2010 Jun; 8(4):347-54. PubMed ID: 20353387
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
[TBL] [Abstract][Full Text] [Related]
20. Trends in uptake of recently approved antiretrovirals within a national healthcare system.
Belperio PS; Mole LA; Boothroyd DB; Backus LI
HIV Med; 2010 Mar; 11(3):209-15. PubMed ID: 19863620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
